Eager to redeem its Covid-19 vaccine, AstraZeneca touts 82.4% efficacy for 12-week dosing schedule — but will the FDA buy it?
AstraZeneca and Oxford say they now have clinical evidence that dosing their adenovirus-based Covid-19 vaccine 12 weeks apart — a regimen approved by the UK, perplexing many — can actually render the shots more effective.
The data will be key to AstraZeneca’s attempt to pull itself back to the upper ranks of the vaccine hierarchy, where it’s struggled as skeptics poke holes in its efficacy while production delays trigger heated disputes with the EU. But it remains to be seen what impact, if any, the analysis will have on the FDA’s thinking and decisions regarding the vaccine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
